Publicaciones RedinRen

• BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure.

  Loureiro J, Schilte M, Aguilera A, Albar-Vizcaíno P, Ramírez-Huesca M, Pérez-Lozano ML et al.. Nephrol Dial Transplant. 2010 Apr;25(4):1098-108.

• PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.

  Sandoval P, Loureiro J, González-Mateo G, Pérez-Lozano ML, Maldonado-Rodríguez A, Sánchez-Tomero JA et al.. Lab Invest. 2010 Oct;90(10):1517-32.

• Paricalcitol Reduces Peritoneal Fibrosis in Mice through the Activation of Regulatory T Cells and Reduction in IL-17 Production.

  González-Mateo GT, Fernández-Míllara V, Bellón T, Liappas G, Ruiz-Ortega M, López-Cabrera M et al.. PLoS One. 2014;9(10):e108477.

• Cost-effectiveness analysis of the Spanish renal replacement therapy program.

  Villa G, Fernández-Ortiz L, Cuervo J, Rebollo P, Selgas R, González T. Perit Dial Int. 2012 Mar-Apr;32(2):192-9.

• Effect of self-administered intraperitoneal bemiparin on peritoneal transport and ultrafiltration capacity in peritoneal dialysis patients with membrane dysfunction. A randomized, multi-centre open clinical trial.

  Del Peso G, Bajo MA, Fontán MP, Martínez J, Marrón B, Selgas R. Nephrol Dial Transplant. 2012 May;27(5):2051-8.

• Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells.

  Fernández-Perpén A, Pérez-Lozano ML, Bajo MA, Albar-Vizcaino P, Sandoval Correa P, del Peso G. Perit Dial Int. 2012 May-Jun;32(3):292-304.

• Start-up of a clinical sample processing, storage and management platform: organisation and development of the REDinREN Biobank.

  Calleros L, Cortés MA, Luengo A, Mora I, Guijarro B, Martín P. Nefrologia. 2012;32(1):28-34.

• Two-in-one protocol: simultaneous small-pore and ultrasmall-pore peritoneal transport quantification.

  Bernardo AP, Bajo MA, Santos O, del Peso G, Carvalho MJ, Cabrita A. Perit Dial Int. 2012 Sep-Oct;32(5):537-44.

• Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.

  Portolés J, López-Sánchez P, Bajo MA, Castellano I, del Peso G, Rodríguez JR. Perit Dial Int. 2012 Mar-Apr;32(2):208-11.

• Thyroid function tests in acute kidney injury.

  Iglesias P, Olea T, Vega-Cabrera C, Heras M, Bajo MA, del Peso G. J Nephrol. 2013 Jan-Feb;26(1):164-72.

• Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria.

  Peces R, Aguilar A, Vega C, Cuesta E, Peces C, Selgas R. Nefrologia. 2012;32(2):160-5.

• Hypoxia inducible factor 1-alpha (HIF-1 alpha) is induced during reperfusion after renal ischemia and is critical for proximal tubule cell survival.

  Conde E, Alegre L, Blanco-Sánchez I, Sáenz-Morales D, Aguado-Fraile E, Ponte B. PLoS One. 2012;7(3):e33258.

• Cost comparison between haemodialysis and peritoneal dialysis outsourcing agreements.

  Arrieta J, Rodríguez-Carmona A, Remón C, Pérez-Fontán M, Ortega F, Sánchez-Tomero JA. Nefrologia. 2012;32(2):247-8; author reply 249-50.

• The influence of initial peritoneal transport characteristics, inflammation, and high glucose exposure on prognosis for peritoneal membrane function.

  Fernández-Reyes MJ, Bajo MA, Del Peso G, Ossorio M, Díaz R, Carretero B. Perit Dial Int. 2012 Nov-Dec;32(6):636-44.

• Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.

  Iglesias P, Selgas R, Romero S, Díez JJ. Eur J Endocrinol. 2012 Sep;167(3):301-9.

• Thrombotic microangiopathy associated with use of interferon-beta.

  Olea T, Díaz-Mancebo R, Picazo ML, Martínez-Ara J, Robles A, Selgas R. Int J Nephrol Renovasc Dis. 2012;5:97-100.

• A novel and de novo deletion in the OCRL1 gene associated with a severe form of Lowe syndrome.

  Peces R, Peces C, de Sousa E, Vega C, Selgas R, Nevado J. Int Urol Nephrol. 2013 Dec;45(6):1767-71.

• Selenium and kidney disease.

  Iglesias P, Selgas R, Romero S, Díez JJ. J Nephrol. 2013 Mar-Apr;26(2):266-72.

• Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.

  Vega-Cabrera C, Del Peso G, Bajo A, Picazo ML, Rivas-Becerra B, Benitez AL. Int Urol Nephrol. 2013 Dec;45(6):1785-9.

• Pseudopheochromocytoma as a cause of resistant and paroxysmal hypertension successfully treated by percutaneous renal denervation.

  Costero O, Sánchez-Recalde A, Moreno R, Moreno I, Selgas R, López-Sendón JL. Rev Esp Cardiol. 2013 Mar;66(3):227-9.

• Adherence to treatment, emotional state and quality of life in patients with end-stage renal disease undergoing dialysis.

  García-Llana H, Remor E, Selgas R. Psicothema. 2013 Feb;25(1):79-86.

• Repeated analysis of estimated insulin resistance using the HOMAIR index in nondiabetic patients on peritoneal dialysis and its relationship with cardiovascular disease and mortality.

  Sánchez-Villanueva R, Estrada P, del Peso G, Grande C, Díez JJ, Iglesias P. Nefrologia. 2013 Jan 18;33(1):85-92.

• Nurse-psychologist interdisciplinary approach for advanced chronic kidney disease consultations: objectives and protocol.

  García-Llana H, Rodríguez-Rey R, Celadilla O, Bajo A, Sánchez-Villanueva R, del Peso G. Nefrologia. 2013 Jan 18;33(1):139-40.

• Are the Mesothelial-to-Mesenchymal Transition, Sclerotic Peritonitis Syndromes, and Encapsulating Peritoneal Sclerosis Part of the Same Process?

  Loureiro J, Gónzalez-Mateo G, Jimenez-Heffernan J, Selgas R, López-Cabrera M, Aguilera Peralta A. Int J Nephrol. 2013;2013:263285.

• Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transition.

  Pérez-Lozano ML, Sandoval P, Rynne-Vidal A, Aguilera A, Jiménez-Heffernan JA, Albar-Vizcaíno P. PLoS One. 2013;8(4):e60776.

• Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.

  Loureiro J, Sandoval P, del Peso G, Gónzalez-Mateo G, Fernández-Millara V, Santamaria B. PLoS One. 2013;8(4):e61165.

• Vancomycin-induced acute kidney injury detected by a prospective pharmacovigilance program from laboratory signals.

  Ramírez E, Jiménez C, Borobia AM, Tong HY, Medrano N, Krauel-Bidwell L. Ther Drug Monit. 2013 Jun;35(3):360-6.

• Activation of vitamin D receptors in the optimization of hyperparathyroidism secondary to dialysis.

  Herrero JA, López-Gómez JM, Maduell F, Martín-de Francisco ÁL, Martín-Malo A, Martínez-Castelao A. Nefrologia. 2013;33(4):571-84.

• Pretransplant peritoneal dialysis relative to hemodialysis improves long-term survival of kidney transplant patients: a single-center observational study.

  López-Oliva MO, Rivas B, Pérez-Fernández E, Ossorio M, Ros S, Chica C. Int Urol Nephrol. 2014 Apr;46(4):825-32.

• Motivational interviewing promotes adherence and improves wellbeing in pre-dialysis patients with advanced chronic kidney disease.

  García-Llana H, Remor E, del Peso G, Celadilla O, Selgas R. J Clin Psychol Med Settings. 2014 Mar;21(1):103-15.

• Thyrotropin and free thyroxine concentrations do not affect cardiovascular disease and mortality in euthyroid peritoneal dialysis patients.

  Pérez SR, Díez JJ, Bajo MA, Iglesias P, Grande C, del Peso G. Perit Dial Int. 2013 Nov-Dec;33(6):697-700.

• Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.

  López-Oliva MO, Martinez V, Buitrago A, Jiménez C, Rivas B, Escuin F. Transplantation. 2014 Apr 27;97(8):839-45.

• [Complications associated with renal graft biopsy in transplant patients].

  Tapia-Canelas C, Zometa R, López-Oliva MO, Jiménez C, Rivas B, Escuin F. Nefrologia. 2014;34(1):115-9.

• [Evaluation of a Nutritional Intervention Program in advanced chronic kidney disease (ACKD) patients].

  Pérez-Torres A, González E, Bajo MA, Palma Milla S, Sánchez-Villanueva R, Bermejo LM. Nutr Hosp. 2013 Nov 1;28(6):2252-60.

• CAN EPS DEVELOPMENT BE AVOIDED WITH EARLY INTERVENTIONS? THE POTENTIAL ROLE OF TAMOXIFEN--A SINGLE-CENTER STUDY.

  De Sousa-Amorim E, Del Peso G, Bajo MA, Alvarez L, Ossorio M, Gil F. Perit Dial Int. 2014 Mar 1;.

• High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies.

  Castillo I, Martinez-Ara J, Olea T, Bartolomé J, Madero R, Hernández E. Kidney Int. 2014 Mar 19;.

• Pseudopheochromocytoma as a cause of resistant and paroxysmal hypertension successfully treated by percutaneous renal denervation.

  Costero O, Sánchez-Recalde A, Moreno R, Moreno I, Selgas R, López-Sendón JL. Rev Esp Cardiol (Engl Ed). 2013 Mar;66(3):227-9.

• Peritoneal dialysis.

  Kratochwill K, Boehm M, Herzog R, Kuster L, Gleiss A, Aufricht C. Nephrol Dial Transplant. 2014 May;29 Suppl 3:iii16-iii18.

• Peritoneal dialysis 1.

  Fotheringham J, Campbell MJ, Wilkie M, Lopes Barreto D, Sampimon DE, Struijk DG. Nephrol Dial Transplant. 2014 May;29 Suppl 3:iii223-iii232.